Stock Update: Oracle Corporation (NYSE:ORCL) – Oracle Health Sciences to Provide Clinical E-Monitoring Solution to Bayer HealthCare

[Marketwired] – Boosting clinical development productivity and efficiency is a top priority for life sciences organizations. To that end, Oracle today announced that two of its core Health Sciences offerings — Oracle … Read more on this. Oracle Corporation (ORCL) , valued at $147.76B, started trading this morning at $35.42. Looking at the equity, the company’s one day range is $35.17 to $36.13 and has traded between $33.13 and $45.24 over the past 12 months. Oracle (ORCL) shares are currently priced at 13.70x this year’s forecasted earnings, which makes them relatively expensive compared to the industry ’s 5.13x earnings multiple for the same period. The company pays shareholders $0.60 per share annually in dividends, yielding 1.68%. In a review of the consensus earnings estimate this quarter, 33 sell-side analysts are looking at $0.62 per share, which would be $0.06 worse than the year-ago quarter and a $0.03 sequential decrease. The full-year EPS estimate is $2.60 which would be a $0.17 worse than last year’s full-year earnings. The quarterly earnings estimate is based on a consensus revenue forecast of the current quarter of $9.13 Billion. If realized, that would be a 2.14% decrease over the year-ago quarter. Recently, BMO Capital Markets Initiated ORCL at Market Perform (Jan 8, 2016). Previously, Morgan Stanley downgraded ORCL from Overweight to Equal-Weight. The average price target for ORCL shares by the analysts covering the stock is $43.91, which is 23.97% above where the stock opened this morning. See more in (NYSE:ORCL) Similar Articles: Stock Update: Oracle Corporation (NYSE:ORCL) – Analyzing Oracle’s Return on Equity (ROE) (ORCL) Market Update: Oracle Corporation (NYSE:ORCL) – Oracle (ORCL) Stock Falling on Rating Downgrade at JMP Securities Company Update: Oracle Corporation (NYSE:ORCL) – Oracle (ORCL) Stock Down on Maxymiser Acquisition